Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2021-07-01 Regulatory Filings
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Response to ASX Price Query 4 pages 842.4KB
Regulatory Filings Classification · 100% confidence The document is a letter from Living Cell Technologies Limited responding to a price query from the Australian Securities Exchange (ASX). It addresses questions about unusual trading activity and compliance with ASX Listing Rules, specifically Listing Rule 3.1 regarding continuous disclosure. The document is a regulatory response to a market query and does not contain financial statements, earnings data, or detailed financial analysis. It is not an annual report, earnings release, or any other financial report but rather a compliance communication with the exchange. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents.
2021-07-01 English
Business Update 2 pages 436.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement titled 'Business Update from LCT Board' dated 10 June 2021. It provides a business update regarding the company's strategic direction, ongoing discussions about new projects, and financial conservation efforts. There are no financial statements, detailed financial results, or regulatory filings such as annual or interim reports. The document is a corporate announcement about business status and strategy, not a report or detailed financial disclosure. It is not a call transcript, earnings release, or management report. The content fits best as a general regulatory announcement or business update under ASX listing rules. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2021-06-09 English
Quarterly Activity Report and Appendix 4C 7 pages 788.7KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly Cash Flow Report 31 March 2021' and is an ASX announcement. It contains detailed quarterly cash flow statements, including operating, investing, and financing activities, as well as commentary on cash balances and payments. The document references the ASX Listing Rule 4.7B, which mandates quarterly cash flow reporting for listed entities. The content includes actual financial data for the quarter ended 31 March 2021, such as cash flows, cash balances, and payments to related parties. This matches the characteristics of an Interim / Quarterly Report (IR), which provides comprehensive financial data for a period shorter than a full fiscal year. The document is not merely an announcement of a report but contains substantive financial data and analysis. Therefore, the correct classification is IR (Interim / Quarterly Report). Q3 2021
2021-04-26 English
LCT exits peptide projects 2 pages 448.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Living Cell Technologies Limited dated 29 March 2021. It announces the termination of peptide research projects and related license contracts with the University of Auckland. The content is a brief update on company activities and does not contain financial statements, detailed financial data, or regulatory filings such as annual or interim reports. It is not a report publication announcement since it contains substantive information about the company's project termination. The document is a corporate announcement about project status and company operations, fitting best under the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-03-28 English
Half Yearly Report and Accounts 21 pages 1.4MB
Interim / Quarterly Report Classification · 100% confidence The document is titled as a 'Half yearly report ended 31 December 2020' and includes detailed financial information such as consolidated loss, net assets, cash flows, and directors' report for the half year period ending 31 December 2020. It contains substantive financial data and analysis, including statements of profit or loss, financial position, changes in equity, cash flows, notes to financial statements, and auditor's review report. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of the half yearly period and comprehensive financial statements aligns with the definition of an Interim / Quarterly Report (IR). Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2021
2021-02-24 English
Change in substantial holding 2 pages 64.2KB
Regulatory Filings
2021-02-16 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.